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Abstract Limited data are available on temocillin susceptibili-
ties in Enterobacteriaceae from Asian countries where antimi-
crobial resistance is prevalent. The in vitro activities of temocillin
and 15 commonly used antimicrobials against 613 non-duplicate
blood (n = 310) and urine (with clinically significant bacteriuria;
n = 303) isolates of Enterobacteriaceae from patients who
attended 3 out of 7 clusters of public hospitals of the Hospital
Authority, HongKong, during 2015/2016were tested.Minimum
inhibitory concentrations (MICs) were determined by Clinical
and Laboratory Standards Institute (CLSI) microbroth dilution
(agar dilution with fosfomycin). For temocillin, MICs were also
obtained using the British Society of Antimicrobial
Chemotherapy (BSAC) microbroth dilution method and
interpreted using the BSAC breakpoints. Overall, 93.0% (570)
isolates were susceptible to temocillin using BSAC systemic
breakpoint (≤8 mg/L) and all except 2 isolates were susceptible
using the urinary breakpoint (≤32mg/L). The extended spectrum
beta-lactamase (ESBL) positivity rate was 23.2% (118 out of 508
E. coli, Klebsiella spp., Proteus spp.). Temocillin resistance rate
to ESBL-positive isolates was 16.1% using the systemic
breakpoint of ≤8 mg/L (MIC50 and MIC90 were 8 mg/L and
16 mg/L respectively). Two isolates (1 E. coli, temocillin MIC
64 mg/L, 1 Klebsiella sp., MIC 32 mg/mL) were resistant to
meropenem and possessed theNDM-5 andKPC-2 genes respec-
tively. Other susceptibility rates were: amoxicillin/clavulanate
(59.1%), trimethoprim/sulfamethoxazole (62.5%), ciprofloxacin
(71.5%), ceftriaxone (75.4%), nitrofurantoin (76.4%), gentami-
cin (78.3%), cefepime (81.1%), ceftazidime (83.5%),
piperacillin/tazobactam (86%), colistin (88.8%), tigecycline
(89.4%), fosfomycin (92.8%), ertapenem (99.0%), amikacin
(99.2%) and meropenem (99.7%). Temocillin may be a useful
alternative for the treatment of infections caused by ESBL and
multi-drug-resistant Enterobacteriaceae in Hong Kong, particu-
larly as resistance rates to ciprofloxacin, nitrofurantoin and
piperacillin/tazobactam are high.
Introduction
The global pandemic of CTX-M extended spectrum beta-
lactamases (ESBLs) has driven rates of multi-drug-resistant
Gram-negative bacteria (MDRGNB) to unprecedented
levels, particularly in Asia [1]. This is exemplified by recent
data reporting an ESBL rate in E. coli of 66% in China [2],
whereas in Hong Kong, 20% of E. coli and 15.4% of
K. pneumoniae causing bacteraemia in hospitalized patients
had been reported to be ESBL-positive isolates [3, 4]. The
spread of carbapenemase-producing Enterobacteriaceae
brought further concerns around carbapenem overuse togeth-
er with the need for heightened infection control.
Temocillin has been introduced into the UK and a number
of European countries for the treatment of infections caused by
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ESBL-producing Enterobacteriaceae [5, 6]. Temocillin, a nar-
row spectrum penicillin (6-α-methoxy-ticarcillin) with intrin-
sic stability to AmpCs, ESBLs and some carbapenemases, has
been considered potentially a Bcarbapenem-sparing agent^, es-
pecially in the treatment of ESBL-producing enterobacterial
infections of the urinary tract [7]. However, limited data exist
on the activity of temocillin against Enterobacteriaceae in
Asian countries and China. We thus sought to evaluate the
in vitro activity of temocillin and commonly used antimicro-
bials (including fosfomycin, tigecycline and colistin) against
clinical isolates of Enterobacteriaceae in patients with urinary
tract infections and/or bacteraemia in Hong Kong hospitals.
Most laboratories in this region perform antimicrobial suscep-
tibilities based on the Clinical and Laboratory Standards
Institute (CLSI) method, and as the susceptibility to temocillin
had been based on the British Society of Antimicrobial
Chemotherapy (BSAC)-defined MIC breakpoints for
Enterobacteriaceae [8], we also examined and compared its
activity using themicrobroth dilution methods according to the
CLSI and the BSAC methods.
Materials and methods
Bacterial isolates
Non-duplicate isolates of Enterobacteriaceae from blood
(n = 310) or urine (with clinically significant bacteriuria;
n = 303) from patients who attended 3 out of 7 clusters of
hospitals of the Hospital Authority in Hong Kong between
January 2015 and January 2016 were examined. These clusters
provide public hospital care with a catchment area for over 50%
of the Hong Kong population, and isolates included in this
study were from the Prince of Wales Hospital (PWH), North
District Hospital (NDH), Shatin Hospital (SH), Queen Elizabeth
Hospital (QEH) and United Christian Hospital (UCH). Bacterial
identification was based on conventional biochemical methods
and/or use of commercial systems, e.g. API, Vitek or MALDI-
TOF, as established in each hospital’s accredited microbiology
laboratory. The isolates included were E. coli (349), Klebsiella
spp. (109),Proteus spp. (50),Enterobacter spp. (35),Citrobacter
spp. (25), Salmonella spp. (17), Morganella spp. (16), Serratia
spp. (11), Providencia spp. (1).
Antimicrobial susceptibility testing
The minimum inhibitory concentrations (MICs) to 16 antibi-
otics, namely, temocillin, amoxicillin/clavulanate, trimetho-
prim/sulfamethoxazole, ciprofloxacin, nitrofurantoin, genta-
micin, amikacin, ceftriaxone, ceftazidime, cefepime, pipera-
cillin/tazobactam, colistin, tigecycline, fosfomycin, ertapenem
and meropenem, were performed and interpreted according to
the CLSI microbroth dilution method [9, 10]. For fosfomycin,
Mueller–Hinton agar supplemented with glucose-6-phosphate
was used for MIC determination according to the CLSI agar
dilution method [9, 10]. As there are currently no CLSI
breakpoints for temocillin, the MICs to temocillin were per-
formed using the BSAC’s microbroth dilution method [11]
and interpreted according to the BSAC systemic and urinary
breakpoints (≤8 mg/L and ≤32 mg/L respectively) [8]. ESBL
detection was confirmed by the combination disks diffusion
method according to the CLSI, using cefotaxime/ceftazidime
with and without clavulanate [10]. E. coli NCTC 10418 and
P. aeruginosa NCTC 10662 strains were included as controls
in the BSAC method [11]. MIC values of temocillin by the
BSAC vs CLSI methods were compared and MIC agreement
was defined as previously described [12].
Results
The antimicrobial susceptibilities of 613 isolates of
Enterobacteriaceae are listed in Supplementary Tables 1 and 2.
The susceptibility rates to temocillin according to the BSAC
method were 93.0% (570 out of 613) and 100% using the sys-
temic (≤8 mg/L) and urinary (≤32 mg/L) breakpoints respective-
ly. The ESBL positivity rate was 23.2% (118 out of 508 E. coli,
Klebsiella spp., Proteus spp.). The temocillin MIC50 and MIC90
for these ESBL-positive isolates were 8 mg/L and 16 mg/L re-
spectively. The temocillin resistance rate for ESBL-positive
Fig. 1 Distribution of temocillin
minimum inhibitory
concentration values of 613
bacterial isolates according to the
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isolates was 16.1% using the systemic breakpoint of ≤8 mg/L.
Other antimicrobial susceptibility rates were: amoxicillin/
clavulanate (59.1%), trimethoprim/sulfamethoxazole (62.5%),
ciprofloxacin (71.5%), ceftriaxone (75.4%), nitrofurantoin
(76.4%), gentamicin (78.3%), cefepime (81.1%), ceftazidime
(83.5%), piperacillin/tazobactam (86%), colistin (88.8%), tige-
cycline (89.4%), fosfomycin (92.8%), ertapenem (99.0%),
amikacin (99.2%) and meropenem (99.7%). Only two isolates
(1 E. coli (TMOMIC 64 mg/L), 1 Klebsiella species (temocillin
MIC 32 mg/mL) were resistant to meropenem and possessed the
NDM-5 and KPC-2 genes respectively.
When MIC values of temocillin obtained by the CLSI and
BSAC methods were compared, all MIC values obtained by
the CLSI method fell within a two-fold dilution of the MIC
values obtained using the BSAC method (Fig. 1). A good
correlation, R2 = 0.87, was obtained between the two methods
and the overall percentage susceptibilities based on the CLSI
microbroth method remained unchanged.
Discussion
Temocillin provides a therapeutic option in themanagement of
infections caused by multi-drug-resistant Enterobacteriaceae.
In a previous study involving six hospitals in England,
temocillin was used in the treatment of urinary tract and blood-
stream infections caused by ESBL/AmpC-producing
Enterobacteriaceae with high clinical and microbiological
cure rates (of 91% and 92% respectively) [5]. Temocillin
was given 2 g twice daily irrespective of the ESBL/AmpC
production by the infecting organism(s), reaffirming its poten-
tial application as a carbapenem-sparing agent [5].
There is a paucity of susceptibility data for temocillin in
the Asian Pacific region. A Korean study revealed a
temocillin susceptibility rate of 96.8% (335 out of 346) in
E. coli from community-acquired urinary tract infection
(UTI) [13], whereas in another study solely focusing on
ESBL-producing E. coli from patients with community-
acquired acute pyelonephritis [14], susceptibilities varied
with 100% susceptibility (N = 11) in CTX-M-14 strains,
while only 72.7% (n = 11) of CTX-M-15 strains were sus-
ceptible. In a recent study from Singapore, a high suscepti-
bility rate of 95% for both E. coli and K. pneumoniae was
reported when breakpoints for uncomplicated UTIs were ap-
plied; however, the rates were substantially lower when
Bsystemic infection^ breakpoints were used [15].
Currently, the resistance rates to agents such as ciprofloxa-
cin, nitrofurantoin and piperacillin/tazobactam in Hong Kong
are high, necessitating a switch to reserved agents such as
colistin and fosfomycin for treating infections caused by
MDRGNB. Temocillin may be a useful alternative for the
treatment of infections caused by ESBL- and multi-drug-
resistant Enterobacteriaceae in Hong Kong, particularly as a
Bcarbapenem-sparing agent^. To our knowledge, this study is
the first to report the use of the CLSI microbroth dilution
method for the testing of temocillin and a good correlation
of MIC values with temocillin between the BSAC and CLSI
microbroth dilution methods was obtained.
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